Aggregatibacter actinomycetemcomitans, a periodontopathogen, has been associated with several systemic diseases. Herein, we report the protective effect of human lactoferrin (hLF) during A. actinomycetemcomitans bacteremia in lactoferrin knockout (LFKO ؊/؊ ) mice. The prophylactic, concurrent, and therapeutic intravenous (i.v.) administrations of hLF significantly cleared the bacteria from blood and organs. Nevertheless, all modes of hLF administration significantly decreased the concentrations of serum proinflammatory cytokines, such as interferon gamma (IFN-␥), tumor necrosis factor alpha (TNF-␣), interleukin-1␤ (IL-1␤), IL-6, IL-10, and IL-12p70. Additionally, hLF administration significantly decreased hepatic and splenic proinflammatory cytokine expression levels compared to those in the non-hLF-treated group. Furthermore, administration of hLF decreased the serum C-reactive protein level, inducible nitric oxide synthase (iNOS) and myeloperoxidase (MPO) gene expression levels in liver and spleen. hLF treatment has also resulted in a 6-fold decrease in spleen weight with the migration of typical inflammatory cells in infected mice as a result of decreased inflammatory response. These results reveal that hLF protects against A. actinomycetemcomitans bacteremia, as indicated by rapid bacterial clearance and decreased host proinflammatory mediators.
A
ggregatibacter actinomycetemcomitans is the most extensively reported organism found in cases of periodontitis, a chronic inflammatory disease that results in bone resorption, destruction of the connective tissues, and eventual bone loss during later stages of the disease. Oral bacteria very often have the potential to enter the bloodstream as a result of minor trauma, including typical daily activities, such as brushing teeth and certain invasive medical procedures (1) . Therefore, it has been recommended that prophylactic antibiotics be prescribed before medical procedures to limit bacteremia and eventual endocarditis (2) .
The immune system of the host normally protects the body from potentially harmful environmental stimuli by recognizing and responding with multiple immunological reactions. While controlling antigenic stimuli, human lactoferrin (hLF), a major defense protein of the innate immune system, also exerts direct first-line defense through its significant impact on the development of adaptive immune responses. The level of the LF is elevated severalfold during infection against the antigenic stimuli (3, 4). LF has been isolated primarily from human milk and is secreted by glandular epithelial cells. It is also expressed by immune cells and is notably detected in the secondary granules of neutrophils from which it is released during the inflammatory process. LF also has profound modulatory action on the adaptive immune system by promoting the maturation of T-cell precursors into competent helper cells and the differentiation of immature B cells into efficient antigen-presenting cells (3) .
There have been many studies demonstrating the protective effect of LF and LF-derived peptides against in vivo infections in wild-type mouse models (Table 1) (5) (6) (7) (8) (9) (10) . Nonetheless, there is no information about the exclusive protective role of hLF during bacteremia in the absence of endogenous mouse lactoferrin (mLF). We also demonstrated in our previous study that LF knockout (LFKO Ϫ/Ϫ ) mice had a higher alveolar bone loss with increased expression of proinflammatory cytokines as well as chemokines during oral infection with A. actinomycetemcomitans.
We also reported that the oral infection of A. actinomycetemcomitans resulted in a higher level of systemic dissemination in LFKO Ϫ/Ϫ mice than in wild-type mice (11) . Furthermore, oral pathogens have the potential to cause frequent bacteremia, and it is our interest to establish a model for LF to control bacteremia in the absence of mLF. Therefore, in the present study, we examined experimental A. actinomycetemcomitans bacteremia and the eventual patterns of antimicrobial and immunomodulatory activities with respect to hLF treatment in the LFKO Ϫ/Ϫ mouse model.
in pyrogen-free PBS and filter sterilized using 0·2-m-pore Acrodisc filters, was used for i.v. injection or oral feeding without further purification (Gelman Sciences, Ann Arbor, MI). To determine the optimal antimicrobial concentration of hLF against A. actinomycetemcomitans, we used 100 to 500 g/g of mouse body weight. For all other further experiments, 300 g/g mouse body weight was used.
In vivo experimental design. The effect of hLF was determined in seven different sets of experiments in LFKO Ϫ/Ϫ mice, which include the following groups: (i) sham-infected control mice i.v. injected with PBS (control), (ii) mice i.v. injected with hLF (300 g/g body weight) (hLF only), (iii) mice orally fed with hLF (300 g/g body weight) with a micropipette one time per day for 3 days and A. actinomycetemcomitans i.v. injected (oral feeding), (iv) mice i.v. injected with A. actinomycetemcomitans (bacteria only), (v) mice i.v. injected with hLF and with A. actinomycetemcomitans i.v. injected 2 h later (prophylactic), (vi) mice i.v. injected with A. actinomycetemcomitans and hLF at the same time (concurrent), and (vii) mice i.v. injected with A. actinomycetemcomitans and then i.v. injected with hLF 2 h later (therapeutic).
Determination of the viable levels. To determine the effective concentration of hLF against bacterial clearance in the blood, different concentration ranging from 100 to 500 g/g of body weight were tested. The blood samples were collected at different time intervals by cardiac puncture, and serially diluted samples were plated on A. actinomycetemcomitans growth medium (AAGM) plates supplemented with rifampin (24 g/ml). Plates were incubated at 37°C in a 5% CO 2 incubator for 48 h, and the numbers of colonies enumerated were expressed as CFU/ml of blood. To determine the bacterial counts in the organs (brain, heart, kidney, liver, lungs, and spleen), the organs were aseptically removed from the mice and placed in 1 ml of PBS in 50-ml Kendall tissue homogenizers (Tyco Healthcare Group, Mansfield, MA). Following homogenization of the tissues, serially diluted samples were plated on AAGM plates, as described previously. In total, three independent experiments representing three biological replicates were performed, and data were statistically analyzed using one-way analysis of variance (ANOVA) (13) .
CBC. Heparinized blood was obtained by retro-orbital phlebotomy under anesthesia, and the complete blood count (CBC) was determined by using the automated H1 Technicon system. (Antech Diagnostics, New Hyde Park, NY).
Serum analysis. The bioavailability of hLF in mouse serum samples was analyzed using the sandwich enzyme-linked immunosorbent assay (ELISA), as described previously (11) . The serum proinflammatory cytokines were analyzed by Milliplex mouse cytokine/chemokine custom multicytokine detection, and the C-reactive protein (CRP) levels were analyzed using mouse acute-phase kit (Millipore Corporation, Billerica, MA). The Luminex 100 system was used to acquire the results, and MILLIPLEX Analyst software (VigeneTech, Carlisle, MA) was used to analyze the results. Acquisition and analysis have been optimized for multiple parameter measurements as described in the manual.
Real-time RT-PCR gene expression analysis. The extraction of total RNA was carried out using an RNeasy minikit (Qiagen, Inc., Valencia, CA). Real-time reverse transcription (RT)-PCR analysis was carried out according to the manufacturer's protocol (high-capacity cDNA reverse transcription kit with Fast SYBR green master mix; ABI, Foster City, CA). The primer sequences and conditions for the hepatic and splenic cytokine expression levels were followed as reported earlier (11) . The primers used for the expression analysis of the inducible nitric oxide synthase (iNOS) and myeloperoxidase (MPO) are given in Table 2 . Results are the means Ϯ standard errors of the means (SEM) of the duplicate experiments of three independent samples.
Histopathology of spleen. At 48 h postinfection, aseptic collection of spleen was performed as described above. The tissues were fixed in 4% paraformaldehyde for 48 h. Tissue sections were routinely processed, embedded in paraffin, mounted on slides, and stained with hematoxylin and (14) . Tissue sections were observed under an Olympus light microscope at ϫ1,000 magnification. Statistical analysis. Significance of differences between the groups was calculated using Student's t test. Values of P Ͻ 0.05 were considered statistically significant. Continuous variables were compared by pairwise t test for two independent samples. Bonferroni correction was used to protect against multiple comparison. Nonlinear regression was used to determine a best-fit curve for the ELISA standard curve and to generate an R 2 value. The R 2 values of the standard curves for these assays were generally greater than 0.95, with most assays having an R 2 value of 0.99. Assays with standard curves with R 2 values of Ͻ0.9 were repeated. Correlation analysis of two variables was carried out with JMP software SAS 9.1 (SAS, Cary, NC).
RESULTS
The antimicrobial activity of hLF in the blood revealed that a prophylactic injection dose of 300 g of body weight was optimal for bacterial clearance. Therefore, for further experiments, 300 g was used (Fig. 1) . Prophylactic, concurrent, and therapeutic i.v. administrations of hLF revealed that the bacteria were rapidly cleared from the blood compared to the case in the group administered bacteria only (Fig. 2) . Analysis of the bacteria from various organs revealed that i.v. administration of hLF had significantly cleared the bacteria compared to the case in the non-hLF-treated group. However, the oral feeding of hLF did not show a significant decrease in the bacterial count compared to case in the bacteriumonly group. Comparison of the modes of administration of hLF revealed that the concurrent administration was effective against A. actinomycetemcomitans compared to the non-hLF-treated mouse group (Fig. 2) .
Next, the ELISA analysis of the residual hLF in the serum samples showed a significant decrease in the hLF concentrations up to 96 h in all groups tested. Among the groups, concurrent administration had the smallest amount of residual hLF (P ϭ 0.002) compared to the amounts in the other groups. However, oral feeding of hLF prior to A. actinomycetemcomitans bacteremia did not show detectable hLF in the serum samples (Fig. 3) .
The efficacy of hLF on the inhibition of A. actinomycetemcomitans-induced serum proinflammatory mediators was analyzed ( Table 3 ). The experimental bacteremia significantly increased the actinomycetemcomitans in LFKO Ϫ/Ϫ mice. Mice (n ϭ 4) were injected with hLF (100 to 500 g/g of body weight) 2 h before injection of A. actinomycetemcomitans (1 ϫ 10 7 ). Bacterial counts in the blood after 6 h are expressed as mean CFU/ml of blood. Asterisks indicate significance (P Ͻ 0.05) of differences in the bacterial counts between hLF-treated and untreated groups, as calculated from duplicates by Student's t test. serum cytokine levels, including those of interferon gamma (IFN-␥) (P ϭ 0.008), tumor necrosis factor alpha (TNF-␣) (P ϭ 0.01), interleukin-1␤ (IL-1␤) (P ϭ 000), IL-6 (P ϭ 0.05), IL-10 (P ϭ 0.05), and IL-12p70 (P ϭ 0.04) at 48 h postinfection compared to the PBS/hLF-only control group. Analysis of the results indicates a significant decrease in IFN-␥, TNF-␣, IL-1␤, and IL-6 levels in the prophylactic, concurrent, and therapeutic hLF-administered groups. However, there was a higher IL-10 concentration (238 Ϯ 12.3 pg/ml) in the concurrent group, and there were slightly elevated concentrations of both IL-10 and IL12p70 in the group given prophylactic administration compared to the group given therapeutic administration of hLF. Similarly, prophylactic oral feeding of hLF also exhibited higher levels of IL-10 (136 Ϯ 15.6 pg/ml) and IL-12p70 (106 Ϯ 31.5 pg/ml). Analysis of the cytokine release in the serum revealed that the IL-6 level was the maximum concentration (34,312 Ϯ 713 pg/ml) of all cytokines tested in this study, followed by IFN-␥ (Table 3) . Subsequent analysis of proinflammatory cytokine gene expression in the spleen and liver indicated that the concurrent and therapeutic hLF administrations resulted in significant reduction compared to the result in the non-hLF-treated group. However, prophylactic hLF administration did not show a significant decrease in A. actinomycetemcomitans-induced expression of the IL-10 and IL-12 genes. There was no significant decrease in the levels of IL-6, IL-10, and IL-12 observed in the group treated with oral feeding of hLF (Fig. 4) .
Analysis of spleen weights in A. actinomycetemcomitans-infected mice after 96 h revealed that there was a significant increase (381 mg) in the spleen weights compared to those in hLF-treated infected mice (5.12 mg; P ϭ 0.03). All hLF treatment groups were shown to have a significant decrease in their splenic weight compared to the bacterium-only group. However, there was no significant decrease in the splenic weight observed in the oral feeding group (Table 4) . Analysis of the morphological features of the spleen in infected mice revealed the presence of small inflammatory foci with a central area of necrosis. A. actinomycetemcomitans infection led to the migration of different cell populations to the cordal space in the red pulp and also invasion of the white pulp (Fig. 5) .
Analysis of the CRP levels revealed that there was a significant elevation in the bacterium-only group compared to the shaminfected group. Mice treated with hLF alone did not show any increase in CRP level. The prophylactic (P ϭ 0.07), therapeutic (P ϭ 0.002), and concurrent (P ϭ 0.003) hLF administrations significantly reduced the A. actinomycetemcomitans-induced serum CRP levels compared to those in the bacterium-only group (Fig. 6) . Real-time RT-PCR analysis of the other acute-phase reactions, such as iNOS and MPO mRNA expression in the spleen, revealed that all treatment groups showed a significant decrease. Nonetheless, the hLF oral feeding did not show a significant decrease in expression in the liver tissue (Fig. 7) . Shown are relative levels of expression of cytokines in the (i) sham-infected control, (ii) hLF-injected, (iii) A. actinomycetemcomitans-injected, and (iv) hLF-pretreated A. actinomycetemcomitans-injected groups. Results for the (i) control, (ii) hLF-alone, (iii) bacterium-alone, (iv) hLF oral feeding, (v) prophylactic, (vi) therapeutic, and (vii) concurrent treatment groups were calculated by the cycle threshold (2 Ϫ⌬⌬CT ) method using ␤-actin as an internal control. Results are shown as mean fold change Ϯ SEM over uninfected controls. Asterisks indicate statistically significant difference compared to uninfected controls (P Ͻ 0.05), as calculated by Student's t test. a Serum samples were collected at 48 h postinfection from each group, and the significance (*, P Ͻ 0.05) of differences in the reduction of the proinflammatory cytokines analyzed during bacteremia was determined. Different modes of hLF administration (300 g/g body weight) were analyzed for significant differences from the non-hLF-treated groups.
In order to analyze the changes in the complete blood count during A. actinomycetemcomitans infection and hLF administrations, we examined the percentage of peripheral blood. The total lymphocyte count was slightly decreased during infection in hLFtreated or nontreated infected mice. There were increases in neutrophil counts in the hLF-treated (21% Ϯ 1.13%) and bacteriumonly (22% Ϯ 0.71%) groups, as well as in the prophylactic group (15.72% Ϯ 6.19%). There was no significant change in the oral feeding, therapeutic, and concurrent hLF-administered groups. Furthermore, there were no differences seen in the cell counts of monocytes, eosinophils, and basophils among any groups of mice (Table 5) .
DISCUSSION
Recent studies have suggested that the Gram-negative periodontopathogen A. actinomycetemcomitans can easily enter into the bloodstream through routine daily procedures, such as teeth brushing and chewing food. Also, the invasiveness of this strain increases the potential risk of systemic diseases, including infective endocarditis (15, 16) , atherosclerosis (17) , and brain abscesses (18) . More recently, increasing attention has been paid to the innate immunity in combating pathogen infection. LF represents one of the elements of the innate immunity system (19) and is abundant in secretory fluids of mammals and secondary granules of neutrophils (20) . LF is considered an important mediator in host defense against various environmental insults. LF is also considered a first-line defense protein in protection against a multitude of microbial infections and prevention of systemic inflammation (21) .
The present study also showed that i.v. administration of hLF rapidly cleared the bacteria from blood and various organs. There have been several reports demonstrating the protective role of both hLF and bovine lactoferrin (bLF) against systemic diseases and bacteremia in mouse models showing bacterial clearance, diminishing levels of lipopolysaccharide (LPS), or reduction in bacterial induced inflammatory cytokines (Table 1) . Indeed, LF is well documented as having direct antimicrobial activity, including an iron-dependent bacteriostatic property and non-iron-dependent bactericidal action on LPS-bearing Gram-negative bacteria (22) . While suppressing microbial growth, LF also directly exerts its first-line defense activity with significant impact through development of adaptive immune responses. LF, indeed, has a profound modulatory action on the adaptive immune system (23) . It has also been reported that the oral feeding of LF in a rat model exerts a protective effect against colitis via modulation of the immune system and correction of cytokine imbalance (6) . In con- trast, LF oral feeding did not protect the mice against inflammatory bowel disease (IBD) (24) .
It has been shown that LF can also function as an anti-inflammatory factor in that it regulates the production of inflammatory cytokines in a manner similar to that of other anti-inflammatory cytokines (23) . In addition, to being a potential member of firstline host defense; in vitro and in vivo studies suggest that this anti-inflammatory activities may be due to inhibition of several cytokines, including TNF-␣ and IL-1␤, that are key mediators of inflammatory response (19, 25) . It has also been reported that the levels of IL-6 and IL-10 were apparent when hLF was administered as a prophylactic prior to LPS challenge ( Table 1 ). The present study also demonstrates that the injection of hLF greatly reduce the levels of A. actinomycetemcomitans-induced cytokines. However, a previous report on activated murine leukocytes revealed that the levels of IL-10 and IL-12 are increased during hLF treatment in vitro. At this point, with the available information, it is difficult to explain the immunomodulatory role of hLF on these cytokines. Further investigation is required to elucidate the underlying mechanism of hLF administration on IL-10 and IL-12 in LFKO Ϫ/Ϫ mice. It has been reported that hLF has the ability to increase neutrophil migration in peripheral blood and in organs (19) . Also, it was demonstrated that the induction of IL-6 and TNF-␣ by i.v. hLF injection could contribute to the increased mobilization of neutrophils from the bone marrow (26) . The results of this study also show increased IL-6 and TNF-␣ expression and thus may contribute to bacterial clearance. It has also been shown that bLF can stimulate phagocytic activity of human neutrophils during infection (20) . The anti-infective effect of hLF against A. actinomycetemcomitans may be multifactorial. Since antimicrobial and antiinflammatory activities have been described for hLF in vitro, it is possible that hLF exerts both of these properties in our infection model. In vivo studies have shown that hLF downregulates dextran sulfate-induced IL-1␤ production (27) . Thus, the anti-inflammatory capacity of hLF in our model could be a consequence of either its antibacterial activity, downregulation of inflammatory cytokines, or both.
We also noticed that hLF has the ability to inhibit LPS-induced acute-phase responses, such as serum CRP levels as well as iNOS and MPO mRNA expression in spleen (28, 29) . It has been reported that hLF treatment can decrease the serum CRP levels in many systemic diseases (30) . The present study documents the decrease of splenic and hepatic immune responses and iNOS and MPO expression. Similarly, in a previous report, A. actinomycetemcomitans LPS stimulation resulted in higher levels of splenic immune responses (31) . Morphological and histological observations of spleen have shown strong evidence that hLF treatment can decrease the levels of inflammatory responses compared to those in hLF-nontreated A. actinomycetemcomitans-infected mice. From the clinical point of view, the spleen plays a major role in bacterial clearance during bacteremia, as evidenced by its enlarged and morphologically differentiated appearance (32) . We also found migration of different cell types in the spleen (33) . However, in hLF-treated mice, the inflammation was decreased upon infection and was similar to that in sham-infected animals, as evidenced by the reduction in the spleen weight and decrease in the expression of cytokine mRNA levels (34, 35) .
It has been documented that both LPS or bacterial challenge and LF administration lead to chemotaxis of the peripheral neutrophils. The present study has also shown a significant increase in neutrophil migration. At this point, the increased neutrophil migration in hLF administration groups could be due to effects of both A. actinomycetemcomitans as well as hLF. In conclusion, in A. actinomycetemcomitans-induced bacteremia, the present study demonstrated that mice i.v. administered hLF cleared the bacteria more rapidly than those orally administered hLF. a Mice (n ϭ 8) were used around 7 weeks of age at the time of analysis. *, significant difference (P Ͻ 0.05) from the control and/or hLF treatment group.
